Glenmark Pharmaceuticals Limited (GLENMARK) AI Stock Analysis

• Market Cap: ₹522.88B
• Dividend Yield: 0.14%
• Average Volume (3M): 28.97K
• Price to Earnings (P/E): 69.7
• Beta (1Y): 0.69
• Revenue Growth: 10.99%
• EPS Growth: N/A
• Country: IN
• Employees: 14,989
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.66
• Shares Outstanding: 282,200,800
• 10 Day Avg. Volume: 44,119
• 30 Day Avg. Volume: 28,971
• PEG Ratio: -0.24
• Price to Book (P/B): 4.81
• Price to Sales (P/S): 3.19
• P/FCF Ratio: -27.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,813.33
• Price Target Upside: -1.62% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

• Rating: 48 Neutral
• Price Target: ₹1,943.00 ▲(5.41% Upside)

Glenmark Pharmaceuticals faces significant challenges with its financial performance, particularly in terms of profitability volatility and liquidity concerns. The technical analysis indicates bearish momentum, and the high P/E ratio suggests overvaluation. These factors collectively contribute to a cautious outlook for the stock.

Glenmark Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

How the Company Makes Money

Glenmark Pharmaceuticals generates revenue through multiple streams, primarily from the sale of its branded generics and generic pharmaceuticals across various markets, including India, the United States, and Europe. The company leverages its extensive research and development capabilities to innovate and bring new products to market, which allows it to maintain a competitive edge. Key revenue streams include sales of prescription drugs, which contribute significantly to the company's income, along with a growing segment of over-the-counter products. Additionally, Glenmark earns revenue through the manufacture and supply of active pharmaceutical ingredients (APIs) to other pharmaceutical companies. Strategic partnerships and collaborations with global pharma companies enhance its product offerings and market reach, further contributing to its earnings. The company also invests in biosimilars and specialty pharmaceuticals, which are becoming increasingly important in its overall revenue model.

Glenmark Pharmaceuticals Limited Financial Statement Overview

Summary

Glenmark Pharmaceuticals shows strong revenue growth and stable operational efficiency, but faces challenges with profitability volatility and high leverage. Liquidity concerns are evident due to negative cash flows, necessitating improved cash management.

Income Statement

Glenmark Pharmaceuticals has shown robust revenue growth over the years, with a significant increase in Total Revenue from the previous periods. However, the Net Profit Margin is volatile, impacted by inconsistent net income figures. The EBIT and EBITDA margins are stable, indicating efficient core operations despite the net income fluctuations. Overall, there is strong revenue growth with profitability challenges.

Balance Sheet

The company's debt levels are relatively high compared to its equity, as reflected in the Debt-to-Equity ratio, which poses a risk if not managed carefully. However, the Return on Equity (ROE) is moderate, and the Equity Ratio suggests a reasonable proportion of assets financed by equity. The balance sheet shows a need for improved leverage management.

Cash Flow

Glenmark's cash flow from operations is negative in recent years, highlighting potential liquidity issues. The Free Cash Flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. The Operating Cash Flow to Net Income Ratio shows a disconnect between reported earnings and cash generation, necessitating closer management of operational cash flows.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	133.13B	133.63B	126.45B	116.56B	123.05B	109.44B
Gross Profit	88.82B	88.38B	80.66B	72.45B	77.57B	70.97B
EBITDA	22.18B	21.68B	18.30B	14.29B	19.12B	19.45B
Net Income	7.54B	10.47B	-15.02B	2.97B	9.42B	9.70B
Balance Sheet
Total Assets	0.00	160.50B	143.59B	193.72B	170.83B	156.04B
Cash, Cash Equivalents and Short-Term Investments	17.05B	17.68B	16.64B	11.73B	14.43B	11.47B
Total Debt	0.00	24.73B	12.31B	46.08B	39.62B	49.86B
Total Liabilities	-88.49B	72.00B	65.11B	95.32B	76.45B	85.39B
Stockholders Equity	88.49B	88.49B	78.48B	94.74B	90.87B	70.65B
Cash Flow
Free Cash Flow	0.00	-15.77B	-11.64B	176.29M	3.19B	3.56B
Operating Cash Flow	0.00	-8.28B	-2.65B	6.25B	11.09B	11.31B
Investing Cash Flow	0.00	20.94M	45.44B	-5.28B	-3.33B	-6.75B
Financing Cash Flow	0.00	7.87B	-39.06B	-774.56M	-5.20B	-4.42B

Glenmark Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1843.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLENMARK, the sentiment is Negative. The current price of 1843.25 is below the 20-day moving average (MA) of 1894.59, below the 50-day MA of 1962.73, and above the 200-day MA of 1684.50, indicating a neutral trend. The MACD of -46.15 indicates Positive momentum. The RSI at 35.02 is Neutral, neither overbought nor oversold. The STOCH value of 20.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GLENMARK.

Glenmark Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	―	₹630.26B	18.58	―	0.36%	7.76%	-2.84%
ALKEM	―	₹663.10B	29.02	―	0.81%	4.49%	11.22%
LUPIN	―	₹893.78B	23.70	―	0.61%	12.40%	63.16%
GLAXO	―	₹465.11B	48.87	―	2.04%	6.65%	48.47%
BIOCON	―	₹498.48B	114.16	―	0.13%	6.80%	-75.66%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GLENMARK	―	₹522.88B	69.69	―	0.14%	10.99%	―

Glenmark Pharmaceuticals Limited Corporate Events

Glenmark Pharmaceuticals to Launch Ropivacaine Hydrochloride Injection in the USA

Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., is set to launch Ropivacaine Hydrochloride Injection USP in various dosages, which is bioequivalent to Naropin® Injection by Fresenius Kabi USA. This launch, beginning in November 2025, enhances Glenmark’s injectable portfolio and underscores its commitment to providing affordable, quality alternatives in the pharmaceutical market. The Naropin® market achieved sales of approximately $20.9 million over a year, highlighting the potential impact of Glenmark’s new product on its market positioning and offerings.